|
|
Blood, 1 April 2005, Vol. 105, No. 7, pp. 2973-2978.
Prepublished online as a Blood First Edition Paper on December 21, 2004; DOI 10.1182/blood-2004-09-3660.
Previous Article | Next Article 
Submitted September 28, 2004
Accepted November 30, 2004
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft versus host disease and disease remission
David B Miklos*, Haesook T Kim, Katherine H Miller, Luxuan Guo, Emmanuel Zorn, Stephanie J Lee, Ephraim P Hochberg, Catherine J Wu, Edwin P Alyea, Corey Cutler, Vincent Ho, Robert J Soiffer, Joseph H Antin, and Jerome Ritz
Department of Medical Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
Department of Medical Oncology and Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA, USA
* Corresponding author; email: DMiklos{at}Stanford.edu.
Minor histocompatibility antigens (mHA) are known targets of donor T cells after allogeneic hematopoietic stem cell transplantation (HSCT). In contrast, B cell responses to mHA have not been extensively characterized and the clinical significance of antibodies to mHA is unknown. We tested 121 HSCT patients and 134 healthy donors for IgG antibodies against 5 mHA encoded by genes on the Y chromosome (DBY, UTY, ZFY, RPS4Y and EIF1AY). Antibodies to at least one H-Y protein developed in 52% of male patients with female donors compared to 8.7% of male patients with male donors (p<0.0001) and in 41.4% of healthy females compared to 7.8% of healthy males (p<0.0001). H-Y antibodies develop 4-12 months after transplantation and persist for long periods. The clinical significance of H-Y antibodies was characterized in 75 male patients with hematologic malignancies who received stem cells from female donors (F M HSCT). The presence of H-Y antibodies correlated with chronic GVHD by univariate (OR=15.5, p<0.0001) and multivariable logistic regression analysis (OR 56.5; p<0.0001). Antibody response to H-Y antigens was also associated with maintenance of disease remission (p<0.0001). B cells may provide a new target for immune intervention in chronic GVHD.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
GVHD and relapse: to B or not to B
- Stephen G. Emerson
Blood 2005 105: 2627-2628.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
A. N. Stumpf, E. D. van der Meijden, C. A. M. van Bergen, R. Willemze, J. H. F. Falkenburg, and M. Griffioen
Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity
Blood,
October 22, 2009;
114(17):
3684 - 3692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. T. Ho, M. Vanneman, H. Kim, T. Sasada, Y. J. Kang, M. Pasek, C. Cutler, J. Koreth, E. Alyea, S. Sarantopoulos, et al.
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
PNAS,
September 15, 2009;
106(37):
15825 - 15830.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Pfistershammer, A. Lawitschka, C. Klauser, J. Leitner, R. Weigl, M. H. M. Heemskerk, W. F. Pickl, O. Majdic, G. A. Bohmig, G. F. Fischer, et al.
Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients
Blood,
September 10, 2009;
114(11):
2323 - 2332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Kim and J. S. Gill
H-Y Incompatibility Predicts Short-Term Outcomes for Kidney Transplant Recipients
J. Am. Soc. Nephrol.,
September 1, 2009;
20(9):
2025 - 2033.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Kuzmina, H. T. Greinix, R. Knobler, N. Worel, M. Kouba, R. Weigl, U. Kormoczi, A. Rottal, D. Pohlreich, C. Zielinski, et al.
Proportions of immature CD19+CD21- B lymphocytes predict the response to extracorporeal photopheresis in patients with chronic graft-versus-host disease
Blood,
July 16, 2009;
114(3):
744 - 746.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Matthews, Z. Lim, B. Afzali, L. Pearce, A. Abdallah, S. Kordasti, A. Pagliuca, G. Lombardi, J. A. Madrigal, G. J. Mufti, et al.
Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab
Haematologica,
July 1, 2009;
94(7):
956 - 966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sarantopoulos, K. E. Stevenson, H. T. Kim, C. S. Cutler, N. S. Bhuiya, M. Schowalter, V. T. Ho, E. P. Alyea, J. Koreth, B. R. Blazar, et al.
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease
Blood,
April 16, 2009;
113(16):
3865 - 3874.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S Bates, A. M. Engemann, and J. M Hammond
Clinical Utility of Rituximab in Chronic Graft-Versus-Host Disease
Ann. Pharmacother.,
February 1, 2009;
43(2):
316 - 321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Kapur, S. Ebeling, and A. Hagenbeek
B-cell involvement in chronic graft-versus-host disease
Haematologica,
November 1, 2008;
93(11):
1702 - 1711.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ofran and J. Ritz
Targets of Tumor Immunity After Allogeneic Hematopoietic Stem Cell Transplantation
Clin. Cancer Res.,
August 15, 2008;
14(16):
4997 - 4999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Friedrichs, S. Siegel, M. Kloess, A. Barsoum, J. Coggin Jr., J. Rohrer, I. Jakob, M. Tiemann, K. Heidorn, C. Schulte, et al.
Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia
J. Immunol.,
May 1, 2008;
180(9):
6374 - 6384.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. V. Rosinski, N. Fujii, J. K. Mito, K. K. W. Koo, S. M. Xuereb, O. Sala-Torra, J. S. Gibbs, J. P. Radich, Y. Akatsuka, B. J. Van den Eynde, et al.
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells
Blood,
May 1, 2008;
111(9):
4817 - 4826.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sarantopoulos, K. E. Stevenson, H. T. Kim, N. S. Bhuiya, C. S. Cutler, R. J. Soiffer, J. H. Antin, and J. Ritz
High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease
Clin. Cancer Res.,
October 15, 2007;
13(20):
6107 - 6114.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Y. Mapara
Stimulating results with stimulatory antibodies
Blood,
July 1, 2007;
110(1):
6 - 7.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Chen, F. M. Ellison, M. A. Eckhaus, A. L. Smith, K. Keyvanfar, R. T. Calado, and N. S. Young
Minor Antigen H60-Mediated Aplastic Anemia Is Ameliorated by Immunosuppression and the Infusion of Regulatory T Cells
J. Immunol.,
April 1, 2007;
178(7):
4159 - 4168.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mullally and J. Ritz
Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation
Blood,
February 15, 2007;
109(4):
1355 - 1362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Sakoda, D. Hashimoto, S. Asakura, K. Takeuchi, M. Harada, M. Tanimoto, and T. Teshima
Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease
Blood,
February 15, 2007;
109(4):
1756 - 1764.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Cutler, D. Miklos, H. T. Kim, N. Treister, S.-B. Woo, D. Bienfang, L. B. Klickstein, J. Levin, K. Miller, C. Reynolds, et al.
Rituximab for steroid-refractory chronic graft-versus-host disease
Blood,
July 15, 2006;
108(2):
756 - 762.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Shizuru
Of mice and men
Blood,
April 1, 2006;
107(7):
2589 - 2590.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Wu, L. Krishnamurti, J. L. Kutok, M. Biernacki, S. Rogers, W. Zhang, J. H. Antin, and J. Ritz
Evidence for ineffective erythropoiesis in severe sickle cell disease
Blood,
November 15, 2005;
106(10):
3639 - 3645.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Lee
New approaches for preventing and treating chronic graft-versus-host disease
Blood,
June 1, 2005;
105(11):
4200 - 4206.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|